Author

A. Le Pape

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

S. Lerondel· 2 shared A. CHAUCHEREAU· 1 shared A. Girault· 1 shared A. J. Garcia-Saez· 1 shared A. Lefevre· 1 shared A. Robert· 1 shared C. GAUDIN· 1 shared C. Vandier· 1 shared

Activity by Year

2016-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Lerondel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Curcumin and NCLX Inhibitors Share Anti-Tumoral Mechanisms in Microsatellite-Instability-Driven Colorectal Cancer

M. Gueguinou, S. Ibrahim, J. Bourgeais, A. Robert, T. Pathak, X. Zhang, D. Crottes, J. Dupuy, D. Ternant, V. Monbet, R. Guibon, H. Flores-Romero, A. Lefevre, S. Lerondel, A. Le Pape, , T. Lecomte

This study identifies NCLX as a therapeutic target in MSI-driven CRC, showing that curcumin and NCLX inhibitors induce anti-tumoral effects through mitochondrial calcium overload and apoptosis.

bioRxiv · Jan 18, 2022Cancer Biology

Regulation of eIF4F complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer

M. F. GARRIDO, N. J. MARTIN, C. GAUDIN, F. Commo, N. AL NAKOUZI, L. FAZLI, E. DEL NERY, J. Camonis, F. Perez, S. LERONDEL, A. LE PAPE, H. ABOU-HAMDAN, M. Gleave, Y. Loriot, L. DESAUBRY, , A. CHAUCHEREAU

This study identifies FKBP7 as a molecular chaperone that regulates the eIF4F complex in taxane-resistant prostate cancer, and shows that inhibiting eIF4A can overcome resistance.

bioRxiv · Dec 22, 2016Cancer Biology